CRISPR Therapeutics AG (CRSP) vs Hinge Health, Inc. (HNGE)
A side-by-side comparison of CRISPR Therapeutics AG and Hinge Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 5, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$55.43HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
HNGE
Hinge Health, Inc.
$97.67HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — CRSP vs HNGE
growth of $100 · dividends reinvested · last 1yCRSP +41.2% (+41.2%/yr)HNGE +160.0% (+160.0%/yr)HNGE compounded faster over this window
CRSP HNGE
CRSP vs HNGE: by the numbers
- •HNGE is the larger company ($7.56B vs $5.35B market cap).
- •HNGE is profitable (15.15% net margin) while CRSP runs a net loss (-3368.72%).
Metrics side by side
Valuation
| Metric | CRSP | HNGE |
|---|---|---|
| P/E ratio | N/A | 75.91 |
| Forward P/E | N/A | 42.12 |
| P/S ratio | 399.21 | 10.50 |
| P/B ratio | 3.06 | 21.95 |
| EV / EBITDA | N/A | 74.49 |
| FCF yield | N/A | 3.80% |
Profitability
| Metric | CRSP | HNGE |
|---|---|---|
| Gross margin | -6537.01% | 84.52% |
| Operating margin | -16191.40% | -92.94% |
| Net margin | -3368.72% | 15.15% |
| ROE | -25.83% | 31.68% |
| ROIC | -21.12% | 26.62% |
Growth (annualized)
| Metric | CRSP | HNGE |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | N/A |
| Total return CAGR (5Y) | -13.01% | N/A |
Frequently asked
- Is CRSP or HNGE more profitable?
- HNGE runs the higher net margin — CRSP at -3368.72% versus HNGE at 15.15%.
Go deeper
Dig into the metrics
Hinge Health P/E ratioCRISPR Therapeutics AG ROEHinge Health ROECRISPR Therapeutics AG operating marginHinge Health operating marginCRISPR Therapeutics AG revenue growthHinge Health revenue growthCRISPR Therapeutics AG free cash flowHinge Health free cash flow
CRISPR Therapeutics AG & Hinge Health appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 5, 2026.